文献速递中医内科中药与中成药合理使用

网络药理学与代谢组学揭示四逆散加减方通过PI3K/Akt/P53/FoxO轴抑制肝癌细胞增殖并诱导凋亡

Metabolomics and integrated network pharmacology analysis reveal SNKAF decoction suppresses cell proliferation and induced cell apoptisis in hepatocellular carcinoma via PI3K/Akt/P53/FoxO signaling axis.
PubMed 文献 · Chin Med · 2022-06-20

该研究通过小鼠模型和体外细胞实验评估SNKAF汤对肝细胞癌的抗癌作用,并结合网络药理学与代谢组学分析其核心靶点和信号通路;结果显示SNKAF汤抑制肿瘤生长(P<0.05)且不引起体重下降,含药血清以时间和浓度依赖方式抑制HCCLM3和MHCC97H细胞增殖,并影响PI3K/Akt/P53/FoxO信号通路主要蛋白。

要点

  • SNKAF汤在动物实验中抑制肝癌生长(P<0.05)且未导致小鼠体重下降。
  • 10%SNKAF含药血清显著影响两株肝癌细胞PI3K/Akt/P53/FoxO通路主要蛋白。
  • 网络药理学与代谢组学联合分析识别217个重叠靶基因,核心包括BCL2、MCL1、Myc、PTEN等。

核心结论

  • SNKAF含药血清在体内外抑制HCCLM3和MHCC97H细胞增殖、迁移、侵袭并诱导肿瘤细胞凋亡。
  • SNKAF汤是肝细胞癌患者有前景的替代治疗选择。

研究设计与样本

  • 建立小鼠模型测量SNKAF汤对肝细胞癌的抗癌效果。
  • 采用细胞活力、克隆和侵袭实验体外研究SNKAF汤对肝癌细胞增殖的抑制作用。
  • 从TCMSP数据库和TCM@Taiwan数据库收集SNKAF成分。
  • 采用代谢组学分析识别SNKAF汤治疗肝细胞癌的潜在基因和通路。
  • 用Western blot检测PI3K、Akt、P53、FoxO蛋白表达。

主要发现

  • 动物实验显示SNKAF汤抑制肿瘤生长(P<0.05)且未引起小鼠体重下降。
  • 体外数据显示SNKAF含药血清以时间和浓度依赖方式抑制HCCLM3和MHCC97H细胞增殖。
  • 网络药理学与代谢组学联合分析显示217个靶基因重叠,核心靶基因包括BCL2、MCL1、Myc、PTEN、gsk3b、CASP9、CREB1、MDM2、pt53和CCND1。
  • SNKAF机制主要涉及癌症相关通路,包括P53、FoxO和PI3K/Akt信号通路,与诱导肿瘤细胞凋亡密切相关。
  • Western bolt验证10%SNKAF血清显著影响两株细胞系中PI3K/Akt/P53/FoxO信号通路的主要蛋白。

关键数值与推荐

  • 动物实验中SNKAF汤抑制肿瘤生长的P值小于0.05。
  • 网络药理学与代谢组学联合分析识别217个重叠靶基因。
  • Western blot验证使用10%SNKAF血清处理两株细胞系。

临床怎么用

  • SNKAF汤可作为肝细胞癌的潜在替代治疗选择,其作用机制可能与调控PI3K/Akt/P53/FoxO信号轴相关。
  • 临床决策时需结合患者具体情况,本研究仅为临床前证据,尚需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is no comprehensive treatment method for hepatocellular carcinoma (HCC); hence, research and development are still focused on systemic therapies, including drugs. Sinikangai fang (SNKAF) decoction, a classic Chinese herbal prescription, has been widely used to treat liver cancer. However, there is no research on its core active component and target. METHODS: Mouse models were established to measure the anticancer effect of SNKAF decoction on HCC. Further, we investigated the effect of SNKAF decoction on inhibition of hepatoma cells proliferation using cell viability, cloning and invasion assays in vitro. The components of SNKAF were collected from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database and TCM@Taiwan database. Metabolomic analysis was used to identify the potential genes and pathways in HCC treated with SNKAF decoction. Then, the expression of phosphoinositide 3-kinase (PI3K), Akt, P53, FoxO proteins of the potential signal pathways were detected using Western blot. RESULTS: The animal experiments showed that SNKAF decoction inhibited tumor growth (P < 0.05) and induced no weight loss in the mice. In vitro data showed that HCCLM3 and MHCC97H cell proliferation was inhibited by SNKAF serum in a time- and concentration dependent manner. Further combined analysis network pharmacology with metabonomics showed that 217 target genes overlapped. The core target genes included BCL2, MCL1, Myc, PTEN, gsk3b, CASP9, CREB1, MDM2, pt53 and CCND1. Cancer-associated pathways were largely involved in SNKAF mechanisms, including P53, FoxO, and PI3K/Akt signaling pathways, which are closely related to induced-tumor cell apoptosis. In addition, Western bolt verified that 10% SNKAF serum significantly affected the main proteins of PI3K/Akt/P53/FoxO signaling pathway in both cell lines. CONCLUSION: SNKAF decoction-containing serum inhibited HCCLM3 and MHCC97H cell proliferation, migration, invasion, and induced-tumor cell apoptosis in-vivo. We confirmed that SNKAF decoction is a promising alternative treatments for HCC patients.

来源:Chin Med,查看原文。版权归原作者所有。

引用

  1. Guo W, Yao X, Lan S, et al. Metabolomics and integrated network pharmacology analysis reveal SNKAF decoction suppresses cell proliferation and induced cell apoptisis in hepatocellular carcinoma via PI3K/Akt/P53/FoxO signaling axis. Chin Med. 2022. PMID: 35725485. doi:10.1186/s13020-022-00628-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。